Floatz logo

Fycompa

Post Traumatic Stress Disorder

Yale UniversityPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Post Traumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB

View all 44 →

Same molecule, other indications

Fycompa is also rated in:

epilepsyDormant
BB
Indicative ·
71 / 100
View asset →
neuralgiaDormant
BB
Indicative ·
66 / 100
View asset →
epilepsyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →